A budget impact model for biosimilar infliximab in Crohns disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 16, Issue 1, 2016, Pages 119-125

  Brodszky, Valentin ^a   Rencz, Fanni ^a,b   Péntek, Márta ^a   Baji, Petra ^a   Lakatos, Péter L ^c   Gulácsi, László ^a  

^a Institute of Data Analytics and Information Systems   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

biosimilar drugs; budget impact analysis; Central and Eastern Europe; Crohn's disease; inflammatory bowel diseases; infliximab

Indexed keywords

BIOSIMILAR AGENT; GASTROINTESTINAL AGENT; INFLIXIMAB;

BUDGET; COST CONTROL; CROHN DISEASE; EASTERN EUROPE; ECONOMIC MODEL; ECONOMICS; HUMAN; REIMBURSEMENT;

BIOSIMILAR PHARMACEUTICALS; BUDGETS; COST SAVINGS; CROHN DISEASE; EUROPE, EASTERN; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; INSURANCE, HEALTH, REIMBURSEMENT; MODELS, ECONOMIC;

EID: 84958173018     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1067142     Document Type: Article

References (27)

1. Cosnes J, Gower, Rousseau C, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140 (6): 1785-94
2. Burisch J, Jess T, Martinato M, Lakatos PL. The burden of inflammatory bowel disease in Europe. J Crohns & colitis 2013; 7 (4): 322-37
3. Nielsen OH, Bjerrum JT, Seidelin JB, et al. Biological treatment of Crohns disease. Dig Dis 2012; 30 (3): 121-33
4. European Medicines Agency. Available from: www.ema.europa.eu/ema/. [Last accessed: 08 September 2014]
5. Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World j gastroenterol 2015; 21 (6): 1728-37
6. National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. Commissioning guide. 2012. Available from: www.nice.org.uk/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fmedia%2fF95%2f42%2fUpdateTA247AndPsoriasisCG.pdf. [Last accessed 03 August 2015]
7. Tothfalusi L, Endrenyi L, Chow SC. Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur J Health Econ 2014; 15 (1): S5-11
8. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73 (3): 492-509
9. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013; 7 (7): 586-9
10. Mularczyk A, Gonciarz M, Bartnik W, et al. Biosimilar medicines-their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2014; 9 (1): 1-3
11. Gecse K, Farkas K, Lovasz B, et al. P314 Biosimilar infliximab in inflammatory bowel diseases: first interim Results from a prospective nationwide observational cohort. J Crohns Colitis 2015; 9 (1): S234
12. Jarzebicka D, Banaszkiewicz A, Plocek A, et al. P295 Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. J Crohns Colitis 2015; 9 (1): S224
13. Sieczkowska J, Banaszkiewicz A, Plocek A, et al. P430 Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: a preliminary report. J Crohns Colitis 2015; 9 (1): S295
14. Yoon Suk J, Park JI, Kim YH, et al. P540 Efficacy and safety of infliximabs biosimilar (REMSIMA) for IBD. J Crohns Colitis 2015; 91: S349-50
15. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 (1): S65-71
16. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17 (1): 5-14
17. Laki J, Monok G, Palosi M, Gajdacsi JZ. Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin Biol Ther 2013; 13 (3): 327-37
18. Department of Medical Expertise Clinical Auditing and Analysis NHIFA. Biological therapy 2006-2010-Analysis 2012
19. Koncz T, Pentek M, Brodszky V, et al. Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin Biol Ther 2010; 10 (9): 1367-78
20. Orlewska E, Gulacsi L. Budget-impact analyses: a critical review of published studies. Pharmacoeconomics 2009; 27 (10): 807-27
21. van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy 2014; 12 (1): 33-40
22. Bakhshai J, Bleu-Laine R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ 2010; 13 (1): 63-9
23. Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohns disease. Health Technol Assess 2011; 15 (6): 1-244
24. Kim J, An Hong J, Kudrin A. P137. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohns Disease in UK, Italy and France. J Crohns Colitis 2015; 9 (1): S144-5
25. Mandel MD, Balint A, Lovasz BD, et al. Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics. Eur J Health Econ 2014; 15 (1): S121-8
26. Gulacsi L, Rotar AM, Niewada M, et al. Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur J Health Econ 2014; 15 (1): 13-25
27. Gulacsi L, Pentek M. HTA in Central and Eastern European countries; the. 2001: a space odyssey and efficiency gain. Eur J Health Econ 2014; 15 (7): 675-80